Recombinant human activated protein C sentenced to the death of a thousand cuts?

Critical Care Medicine

Volumn 35, Issue 6, 2007, Pages 1609-1610

  O'Brien, James M ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Activated protein C; ADDRESS; Drotrecogin alfa (activated); Multiple organ failure; PROWESS; Sepsis; Severe sepsis; Therapy

Indexed keywords

DROTRECOGIN; FIBRINOLYTIC AGENT; PLACEBO;

ACUTE HEART INFARCTION; BLEEDING; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; EDITORIAL; HIGH RISK PATIENT; HUMAN; MORTALITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEPSIS; THORAX PAIN; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; APACHE; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; RESEARCH DESIGN; SEPSIS; SURVIVAL ANALYSIS;

EID: 34249330976     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000267653.72988.21     Document Type: Editorial

References (14)

1. Laterre PF, Abraham E, Janes J, et al: ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation. Crit Care Med 2007; 35:1457-1463
2. Abraham E, Laterre PF, Garg R, et al: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
3. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
4. Drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)]. Online at: http://www.fda.gov/ohrms/dockets/ac/01/ briefing/3797b1_02_FDAbriefing.doc. Accessed April 3, 2007
5. Deans KJ, Minneci PC, Banks SM, et al: Substantiating the concerns about recombinant human activated protein C use in sepsis. Crit Care Med 2004; 32:2542-2543
6. Eichacker PQ, Natanson C: Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med 2007; 33:396-399
7. Eichacker PQ, Natanson C, Danner RL: Surviving sepsis-practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 2006; 355:1640-1642
8. Parrillo JE: Severe sepsis and therapy with activated protein C. N Engl J Med 2005; 353:1398-1400
9. The Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342:1301-1308
10. Aberegg SK, Arkes H, Terry PB: Failure to adopt beneficial therapies caused by bias in medical evidence evaluation. Med Decis Making 2006; 26:575-582
11. Aberegg SK, Haponik EF, Terry PB: Omission bias and decision making in pulmonary and critical care medicine. Chest 2005; 128:1497-1505
12. Lilly plans new clinical trial of Xigris. Online at: http:// lillymedia.com/ReleaseDetail.cfm?ReleaseID=231184. Accessed April 3, 2007
13. Bresalier RS, Sandler RS, Quan H, et al: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092-1102
14. Topol EJ: Failing the public health - Rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351:1707-1709